This page is part of the MII IG Kerndatensatz-Modul Onkologie (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

• Narrative Content
• XML
• JSON

: MII CM Onko ATC Code Changes 2023 to 2024

Active as of 2024-12-12

Raw xml | Download

<ConceptMap xmlns="http://hl7.org/fhir">
  <id value="mii-cm-onko-atc-transitions-2024"/>
  <meta>
    <extension
               url="http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-license">
      <valueCode value="CC-BY-4.0"/>
    </extension>
    <extension url="http://hl7.org/fhir/StructureDefinition/package-source">
      <extension url="packageId">
        <valueId
                 value="de.medizininformatikinitiative.kerndatensatz.onkologie"/>
      </extension>
      <extension url="version">
        <valueString value="2027.0.0-ballot.1"/>
      </extension>
      <extension url="uri">
        <valueUri
                  value="https://www.medizininformatik-initiative.de/fhir/ext/modul-onko"/>
      </extension>
    </extension>
    <profile
             value="http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-shareableconceptmap"/>
    <profile
             value="http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-publishableconceptmap"/>
  </meta>
  <language value="en"/>
  <text>
    <status value="generated"/>
    <div xml:lang="en" lang="en"><hr/><p><b>English</b></p><hr/><p class="res-header-id"><b>Generated Narrative: ConceptMap mii-cm-onko-atc-transitions-2024</b></p><a name="mii-cm-onko-atc-transitions-2024"> </a><a name="hcmii-cm-onko-atc-transitions-2024"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profiles: <a href="http://hl7.org/fhir/uv/crmi/STU2/StructureDefinition-crmi-shareableconceptmap.html">CRMI Shareable ConceptMap</a>, <a href="http://hl7.org/fhir/uv/crmi/STU2/StructureDefinition-crmi-publishableconceptmap.html">CRMI Publishable ConceptMap</a></p></div><p>Mapping from <a href="ValueSet-mii-vs-onko-systemische-therapie-substanzen-2023.html">MII VS Onkologie Systemische Therapie Substanzen ATC 2023</a> to <a href="ValueSet-mii-vs-onko-systemische-therapie-substanzen-2024.html">MII VS Onkologie Systemische Therapie Substanzen ATC 2024</a></p><br/><p>Mapping from <code>http://fhir.de/CodeSystem/bfarm/atc</code> (Atc) to <code>http://fhir.de/CodeSystem/bfarm/atc</code> (Atc)</p><table class="grid"><tr><td><b>Source Code</b></td><td><b>Relationship</b></td><td><b>Target Code</b></td><td><b>Comment</b></td></tr><tr><td>L04AA34 (Alemtuzumab)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L04AG06 (Alemtuzumab)</td><td>Reklassifizierung innerhalb der Immunsuppressiva</td></tr><tr><td>L04AA26 (Belimumab)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L04AG04 (Belimumab)</td><td/></tr><tr><td>L04AA25 (Eculizumab)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L04AJ01 (Eculizumab)</td><td>Reklassifizierung zu Komplement-Inhibitoren</td></tr><tr><td>L04AA21 (Efalizumab)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L04AG02 (Efalizumab)</td><td/></tr><tr><td>L01EG02 (Everolimus)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L04AH02 (Everolimus)</td><td>Zusätzliche Klassifizierung als Immunsuppressivum (behält auch L01EG02)</td></tr><tr><td>L04AA27 (Fingolimod)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L04AE01 (Fingolimod)</td><td>Reklassifizierung zu Sphingosin-1-Phosphat-Rezeptor-Modulatoren</td></tr><tr><td>L04AA13 (Leflunomid)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L04AK01 (Leflunomid)</td><td/></tr><tr><td>L01FX24 (Mosunetuzumab)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01FX25 (Mosunetuzumab)</td><td>Code-Anpassung innerhalb der bispezifischen Antikörper</td></tr><tr><td>L04AA02 (Muromonab-CD3)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L04AG01 (Muromonab-CD3)</td><td/></tr><tr><td>L04AA23 (Natalizumab)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L04AG03 (Natalizumab)</td><td/></tr><tr><td>L01XY03 (Nivolumab und Relatlimab)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01FY02 (Nivolumab und Relatlimab)</td><td>Reklassifizierung zu Kombinationen monoklonaler Antikörper</td></tr><tr><td>L01FA02 (Ofatumumab)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L04AG12 (Ofatumumab)</td><td>Zusätzliche Klassifizierung als Immunsuppressivum (behält auch L01FA02)</td></tr><tr><td>L01XY02 (Pertuzumab und Trastuzumab)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01FY01 (Pertuzumab und Trastuzumab)</td><td>Reklassifizierung zu Kombinationen monoklonaler Antikörper</td></tr><tr><td>L04AA10 (Sirolimus)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L04AH01 (Sirolimus)</td><td>Reklassifizierung zu mTOR-Inhibitoren (Immunsuppressiva)</td></tr></table></div>
  </text>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability">
    <valueCode value="shareable"/>
  </extension>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability">
    <valueCode value="publishable"/>
  </extension>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/artifact-versionPolicy">
    <valueCodeableConcept>
      <coding>
        <system
                value="http://terminology.hl7.org/CodeSystem/artifact-version-policy-codes"/>
        <code value="package"/>
        <display value="Package"/>
      </coding>
    </valueCodeableConcept>
  </extension>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/resource-approvalDate">
    <valueDate value="2026-09-15"/>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-topic">
    <valueCodeableConcept>
      <coding>
        <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
        <code value="C3262"/>
      </coding>
    </valueCodeableConcept>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
    <valueContactDetail>
      <telecom>
        <system value="email"/>
        <value value="thomas.debertshaeuser@charite.de"/>
      </telecom>
    </valueContactDetail>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-editor">
    <valueContactDetail>
      <name value="Taskforce Core Data Set"/>
    </valueContactDetail>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-reviewer">
    <valueContactDetail>
      <name value="Interoperability Working Group"/>
      <telecom>
        <system value="url"/>
        <value
               value="https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group"/>
      </telecom>
    </valueContactDetail>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-reviewer">
    <valueContactDetail>
      <name value="National Steering Committee"/>
      <telecom>
        <system value="url"/>
        <value
               value="https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee"/>
      </telecom>
    </valueContactDetail>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-endorser">
    <valueContactDetail>
      <name value="Interoperability Working Group"/>
      <telecom>
        <system value="url"/>
        <value
               value="https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group"/>
      </telecom>
    </valueContactDetail>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-endorser">
    <valueContactDetail>
      <name value="National Steering Committee"/>
      <telecom>
        <system value="url"/>
        <value
               value="https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee"/>
      </telecom>
    </valueContactDetail>
  </extension>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/artifact-versionAlgorithm">
    <valueCoding>
      <system value="http://hl7.org/fhir/version-algorithm"/>
      <code value="semver"/>
      <display value="SemVer"/>
    </valueCoding>
  </extension>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/resource-effectivePeriod">
    <valuePeriod>
      <start value="2027"/>
    </valuePeriod>
  </extension>
  <url
       value="https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ConceptMap/mii-cm-onko-atc-transitions-2024"/>
  <version value="2027.0.0-ballot.1"/>
  <name value="MII_CM_Onko_ATC_Transitions_2024"/>
  <title value="MII CM Onko ATC Code Changes 2023 to 2024"/>
  <status value="active"/>
  <experimental value="false"/>
  <date value="2024-12-12"/>
  <publisher value="Medizininformatik Initiative"/>
  <contact>
    <name value="Medizininformatik Initiative"/>
    <telecom>
      <system value="url"/>
      <value value="https://www.medizininformatik-initiative.de/"/>
    </telecom>
  </contact>
  <description
               value="Diese ConceptMap dokumentiert die ATC-Code-Änderungen von 2023 zu 2024. Mehrere immunmodulatorische Substanzen wurden in neue Kategorien umklassifiziert, und Kombinationspräparate erhielten neue Codes."/>
  <jurisdiction>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <code value="DE"/>
      <display value="Germany"/>
    </coding>
  </jurisdiction>
  <purpose
           value="Migration von ATC-Codes für immunmodulatorische Substanzen und Kombinationspräparate, die 2024 umkodiert wurden."/>
  <sourceCanonical
                   value="https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2023"/>
  <targetCanonical
                   value="https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2024"/>
  <group>
    <source value="http://fhir.de/CodeSystem/bfarm/atc"/>
    <target value="http://fhir.de/CodeSystem/bfarm/atc"/>
    <element>
      <code value="L04AA34"/>
      <display value="Alemtuzumab"/>
      <target>
        <code value="L04AG06"/>
        <display value="Alemtuzumab"/>
        <equivalence value="equivalent"/>
        <comment value="Reklassifizierung innerhalb der Immunsuppressiva"/>
      </target>
    </element>
    <element>
      <code value="L04AA26"/>
      <display value="Belimumab"/>
      <target>
        <code value="L04AG04"/>
        <display value="Belimumab"/>
        <equivalence value="equivalent"/>
      </target>
    </element>
    <element>
      <code value="L04AA25"/>
      <display value="Eculizumab"/>
      <target>
        <code value="L04AJ01"/>
        <display value="Eculizumab"/>
        <equivalence value="equivalent"/>
        <comment value="Reklassifizierung zu Komplement-Inhibitoren"/>
      </target>
    </element>
    <element>
      <code value="L04AA21"/>
      <display value="Efalizumab"/>
      <target>
        <code value="L04AG02"/>
        <display value="Efalizumab"/>
        <equivalence value="equivalent"/>
      </target>
    </element>
    <element>
      <code value="L01EG02"/>
      <display value="Everolimus"/>
      <target>
        <code value="L04AH02"/>
        <display value="Everolimus"/>
        <equivalence value="equivalent"/>
        <comment
                 value="Zusätzliche Klassifizierung als Immunsuppressivum (behält auch L01EG02)"/>
      </target>
    </element>
    <element>
      <code value="L04AA27"/>
      <display value="Fingolimod"/>
      <target>
        <code value="L04AE01"/>
        <display value="Fingolimod"/>
        <equivalence value="equivalent"/>
        <comment
                 value="Reklassifizierung zu Sphingosin-1-Phosphat-Rezeptor-Modulatoren"/>
      </target>
    </element>
    <element>
      <code value="L04AA13"/>
      <display value="Leflunomid"/>
      <target>
        <code value="L04AK01"/>
        <display value="Leflunomid"/>
        <equivalence value="equivalent"/>
      </target>
    </element>
    <element>
      <code value="L01FX24"/>
      <display value="Mosunetuzumab"/>
      <target>
        <code value="L01FX25"/>
        <display value="Mosunetuzumab"/>
        <equivalence value="equivalent"/>
        <comment
                 value="Code-Anpassung innerhalb der bispezifischen Antikörper"/>
      </target>
    </element>
    <element>
      <code value="L04AA02"/>
      <display value="Muromonab-CD3"/>
      <target>
        <code value="L04AG01"/>
        <display value="Muromonab-CD3"/>
        <equivalence value="equivalent"/>
      </target>
    </element>
    <element>
      <code value="L04AA23"/>
      <display value="Natalizumab"/>
      <target>
        <code value="L04AG03"/>
        <display value="Natalizumab"/>
        <equivalence value="equivalent"/>
      </target>
    </element>
    <element>
      <code value="L01XY03"/>
      <display value="Nivolumab und Relatlimab"/>
      <target>
        <code value="L01FY02"/>
        <display value="Nivolumab und Relatlimab"/>
        <equivalence value="equivalent"/>
        <comment
                 value="Reklassifizierung zu Kombinationen monoklonaler Antikörper"/>
      </target>
    </element>
    <element>
      <code value="L01FA02"/>
      <display value="Ofatumumab"/>
      <target>
        <code value="L04AG12"/>
        <display value="Ofatumumab"/>
        <equivalence value="equivalent"/>
        <comment
                 value="Zusätzliche Klassifizierung als Immunsuppressivum (behält auch L01FA02)"/>
      </target>
    </element>
    <element>
      <code value="L01XY02"/>
      <display value="Pertuzumab und Trastuzumab"/>
      <target>
        <code value="L01FY01"/>
        <display value="Pertuzumab und Trastuzumab"/>
        <equivalence value="equivalent"/>
        <comment
                 value="Reklassifizierung zu Kombinationen monoklonaler Antikörper"/>
      </target>
    </element>
    <element>
      <code value="L04AA10"/>
      <display value="Sirolimus"/>
      <target>
        <code value="L04AH01"/>
        <display value="Sirolimus"/>
        <equivalence value="equivalent"/>
        <comment
                 value="Reklassifizierung zu mTOR-Inhibitoren (Immunsuppressiva)"/>
      </target>
    </element>
  </group>
</ConceptMap>